CN105814021B - 作为激酶抑制剂的取代的烟酰胺衍生物 - Google Patents

作为激酶抑制剂的取代的烟酰胺衍生物 Download PDF

Info

Publication number
CN105814021B
CN105814021B CN201480066924.XA CN201480066924A CN105814021B CN 105814021 B CN105814021 B CN 105814021B CN 201480066924 A CN201480066924 A CN 201480066924A CN 105814021 B CN105814021 B CN 105814021B
Authority
CN
China
Prior art keywords
amino
phenyl
ethynyl
carbonyl
lambda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480066924.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105814021A (zh
Inventor
S·博罗
S·王
T·马隆
J·沃斯特
J·沈
M·罗宾逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN105814021A publication Critical patent/CN105814021A/zh
Application granted granted Critical
Publication of CN105814021B publication Critical patent/CN105814021B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201480066924.XA 2013-12-12 2014-12-10 作为激酶抑制剂的取代的烟酰胺衍生物 Expired - Fee Related CN105814021B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361915186P 2013-12-12 2013-12-12
US201361915209P 2013-12-12 2013-12-12
US61/915,209 2013-12-12
US61/915,186 2013-12-12
PCT/US2014/069601 WO2015089220A1 (en) 2013-12-12 2014-12-10 Substituted nicotinamide derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN105814021A CN105814021A (zh) 2016-07-27
CN105814021B true CN105814021B (zh) 2020-03-13

Family

ID=52118045

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480066924.XA Expired - Fee Related CN105814021B (zh) 2013-12-12 2014-12-10 作为激酶抑制剂的取代的烟酰胺衍生物

Country Status (8)

Country Link
US (2) US20150166518A1 (https=)
EP (1) EP3080084B1 (https=)
JP (1) JP6531100B2 (https=)
CN (1) CN105814021B (https=)
AU (1) AU2014362391B2 (https=)
BR (1) BR112016013539A2 (https=)
CA (1) CA2932831A1 (https=)
WO (1) WO2015089220A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153419A2 (en) 2010-06-03 2011-12-08 Midtronics, Inc. Battery pack maintenance for electric vehicle
US11740294B2 (en) 2010-06-03 2023-08-29 Midtronics, Inc. High use battery pack maintenance
US10046649B2 (en) 2012-06-28 2018-08-14 Midtronics, Inc. Hybrid and electric vehicle battery pack maintenance device
DE112012004706T5 (de) 2011-11-10 2014-08-21 Midtronics, Inc. Batteriepack-Testvorrichtung
US11325479B2 (en) 2012-06-28 2022-05-10 Midtronics, Inc. Hybrid and electric vehicle battery maintenance device
US10843574B2 (en) 2013-12-12 2020-11-24 Midtronics, Inc. Calibration and programming of in-vehicle battery sensors
US10473555B2 (en) 2014-07-14 2019-11-12 Midtronics, Inc. Automotive maintenance system
WO2016123075A1 (en) 2015-01-26 2016-08-04 Midtronics, Inc. Alternator tester
US10608353B2 (en) 2016-06-28 2020-03-31 Midtronics, Inc. Battery clamp
US12320857B2 (en) 2016-10-25 2025-06-03 Midtronics, Inc. Electrical load for electronic battery tester and electronic battery tester including such electrical load
US11054480B2 (en) 2016-10-25 2021-07-06 Midtronics, Inc. Electrical load for electronic battery tester and electronic battery tester including such electrical load
CN108456163A (zh) 2017-02-20 2018-08-28 中国科学院上海药物研究所 含邻氨基杂芳环炔基的化合物及其制备方法和用途
US11513160B2 (en) 2018-11-29 2022-11-29 Midtronics, Inc. Vehicle battery maintenance device
CN111662227B (zh) * 2019-03-06 2022-07-05 中国科学院上海药物研究所 邻氨基吡啶炔类化合物及其制备方法和用途
US11566972B2 (en) 2019-07-31 2023-01-31 Midtronics, Inc. Tire tread gauge using visual indicator
US11545839B2 (en) 2019-11-05 2023-01-03 Midtronics, Inc. System for charging a series of connected batteries
US11668779B2 (en) 2019-11-11 2023-06-06 Midtronics, Inc. Hybrid and electric vehicle battery pack maintenance device
US11474153B2 (en) 2019-11-12 2022-10-18 Midtronics, Inc. Battery pack maintenance system
DE102020216599A1 (de) 2019-12-31 2021-07-01 Midtronics, Inc. Intelligente Modulschnittstelle für eine Batteriewartungsvorrichtung
US11973202B2 (en) 2019-12-31 2024-04-30 Midtronics, Inc. Intelligent module interface for battery maintenance device
US11486930B2 (en) 2020-01-23 2022-11-01 Midtronics, Inc. Electronic battery tester with battery clamp storage holsters
US12517178B2 (en) 2021-05-27 2026-01-06 Midtronics, Inc. Battery monitoring system
US12555965B2 (en) 2021-08-24 2026-02-17 Midtronics, Inc. Power adapter for automotive vehicle maintenance device
US12330513B2 (en) 2022-02-14 2025-06-17 Midtronics, Inc. Battery maintenance device with high voltage connector
US12392833B2 (en) 2022-05-09 2025-08-19 Midtronics, Inc. Electronic battery tester

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061236A2 (en) * 2006-11-16 2008-05-22 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2013062843A1 (en) * 2011-10-20 2013-05-02 Allergan, Inc. Pyridine- sulfoximines as tyrosine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061236A2 (en) * 2006-11-16 2008-05-22 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2013062843A1 (en) * 2011-10-20 2013-05-02 Allergan, Inc. Pyridine- sulfoximines as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
US20160194311A1 (en) 2016-07-07
CA2932831A1 (en) 2015-06-18
US20150166518A1 (en) 2015-06-18
AU2014362391A1 (en) 2016-06-16
AU2014362391B2 (en) 2019-04-04
EP3080084A1 (en) 2016-10-19
EP3080084B1 (en) 2018-06-13
CN105814021A (zh) 2016-07-27
BR112016013539A2 (pt) 2020-10-27
WO2015089220A1 (en) 2015-06-18
JP6531100B2 (ja) 2019-06-12
JP2016539995A (ja) 2016-12-22
US9567324B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
CN105814021B (zh) 作为激酶抑制剂的取代的烟酰胺衍生物
JP6916795B2 (ja) Ｌｓｄ１阻害剤
TWI377198B (en) Novel pyridine derivatives and pyrimidine derivatives (3)
JP5799479B2 (ja) Ｒｈｏキナーゼインヒビター
CN108137507A (zh) 基于mdm2的蛋白水解调节剂和相关的使用方法
JP2008523072A (ja) タンパク質キナーゼの阻害剤
WO2013070657A1 (en) Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
CA2977837A1 (en) Ghrelin o-acyl transferase inhibitors
CA3172589A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
CN105916850B (zh) 作为激酶抑制剂的取代的二烷基(氧撑)-λ4-硫烷亚基烟酰胺衍生物
JP7311918B2 (ja) 新型汎ｒａｆキナーゼ阻害剤及びその使用
CN102066328A (zh) 亚氨基吡啶衍生物及其用途
WO2019119481A1 (zh) 吲唑类衍生物激酶抑制剂
BRPI0610856A2 (pt) diazepanos farmaceuticamente ativos
HK1227390A1 (en) Substituted nicotinamide derivatives as kinase inhibitors
HK1227390B (zh) 作为激酶抑制剂的取代的烟酰胺衍生物
EP3640242A1 (en) Rock-inhibiting compound and uses thereof
RU2792626C1 (ru) Новый ингибитор киназы pan-raf и его применение
HK1228396A1 (en) Substituted dialkyl(oxido)-λ4-sulfanylidene nicotinamide derivatives as kinase inhibitors
US20250312335A1 (en) Flt combination therapy for cancer and compositions therefor
Volkova et al. Optimization of N-Piperidinyl-Benzimidazolone Derivatives as Po-tent and Selective Inhibitors of 8-Oxo Guanine DNA Glycosylase
HK1228396B (zh) 作为激酶抑制剂的取代的二烷基(氧撑)-λ4-硫烷亚基烟酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1227390

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200313

CF01 Termination of patent right due to non-payment of annual fee